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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 INTRODUCTION 
 Cardiovascular disease is an epidemic of modern society. Myocardial 
Infarction is a major cause of morbidity and mortality in the world. Despite the 
impressive strides in diagnosis and management over the past three decades, 
acute myocardial infarction continues to be a major public health problem in 
industrialized world and is becoming an increasingly important problem in 
developing countries. Because acute myocardial infarction may strike an 
individual during the most productive years, it can have profoundly deleterious 
psychosocial and economic ramifications.   
 After rupture of an atherosclerotic plaque in a coronary artery, there is 
platelet adhesion, activation and aggregation leading to the formation of a 
thrombus and ultimately culminating in acute myocardial infarction. So the 
more reactive the platelets are, the higher the chances for myocardial infarction.  
 Bancroft et al (2000) stated that platelet volume is a marker and possibly 
a determinant of platelet function in that, larger platelets are more reactive than 
normal sized platelets.  
 Martin et al (1983) found an association between increased mean platelet 
volume and increased occurrence of myocardial infarction. But studies 
conducted by Halbmayer et al (1995) observed no such association. 
  Thus the role of platelet volume as a risk factor for the occurrence of 
myocardial infarction remains unresolved and further studies are definitely 
needed. Hence the hypothesis considered for the present study is “Platelet 
volume is not associated with myocardial infarction”. However, the proposed 
study will also help to confirm or refute the published reports on platelet 
volume in myocardial infarction.    
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 REVIEW OF LITERATURE 
 The role of platelets in acute myocardial infarction has been appreciated 
for several decades. Yet the last 5-10 years have seen a dramatic increase in the 
understanding, development, clinical evaluation and therapeutic application of 
platelet inhibitor therapy. 
 Platelets play an essential role in haemostasis, thrombosis and 
coagulation of blood. These tiny cells previously described as “sponges” 
(Adelson et al, 1961) are known to engage in a complex repertoire of 
biochemical and molecular activities designed to prevent haemorrhage. 
 
PLATELET STRUCTURAL AND FUNCTIONAL ANATOMY 
Light Microscopy  
 On Wright-Glemsa stained blood smears, platelets appear as small 
anucleate, ovoid  or round cells, with a pale grayish blue cytoplasm that 
contains homogeneously distributed purple-red granules. 
Dimensions  
 The volumes of circulating platelets from a single individual are 
heterogeneous and exhibit a lognormal size distribution; and the platelet volume 
in a single individual (mean platelet volume, MPV) varies from 7 to 9 
 femtolitres. (Paulus, 1975; Martin et al, 1982; Stenberg and Levin, 1989; 
Corash, 1977). 
Electron Microscopy and Subcellular Organelles 
By scanning electron microscopy, circulating blood platelets appear as 
flat discs, with smooth contours and rare spiny filopodia. Scanning electron 
microscopy also reveals random openings of a channel system, the surface 
connected canalicular system, which invaginates throughout the platelet  and is 
the conduit by which granule contents exocytose after stimulation.  Although 
the platelet is anucleate, transmission electron microscopy reveals a cytoplasm 
packed with a number of different organelles essential to the maintenance of 
normal haemostasis. 
Glycocalyx  
 Structure : A glycocalyx, 15 to 20 nm thick, is visualized by 
transmission electron microscopy and contains glycoproteins, glycolipids, 
mucopolysaccharides, and adsorbed plasma proteins. 
 Function : The glycocalyx has a net negative surface charge due to 
sialic acid residues on the proteins and lipids; the charge is thought to minimize 
attachment of circulating platelets to each other (Coller, 1984). This structure is 
rich in carbohydrate moieties of membrane-associated glycoproteins, which 
serve as receptors to mediate transfer of signals by stimulatory agents.  The 
 glycocalyx interacts with platelet activators to facilitate platelet adhesion and 
aggregation. 
Plasma Membrane 
 Structure : The platelet plasma membrane is a typical trilaminar 
membrane with glycoproteins, glycolipids, and cholesterol embedded in a 
phospholipid bilayer. 
 Function :  The plasma membrane contains sodium and calcium ATPase 
pumps, which are important for maintaining ionic homeostasis. It has a 
specialized role in providing a surface for the acceleration of blood coagulation, 
in that a specific platelet coagulant protein, platelet factor 3, resides in this 
lipoprotein-rich unit membrane. 
Surface-connected Canalicular System 
 Structure :  The surface-connected canalicular system, also called the 
open canalicular system, weaves throughout the cell cytoplasm in a tortuous 
fashion. 
 Function : The functions of the surface connected canalicular system 
are to provide a route of entry and egress for molecules, an internal reservoir of 
membrane to facilitate platelet spreading and filopodia formation after adhesion 
and a storage reservoir for membrane glycoproteins that increase on the platelet 
surface after activation. 
 
 Dense Tubular system  
 Structure :  Unlike the surface-connected canalicular system, the dense 
tubular system is a closed-channel system consisting of narrow, membrane 
limited tubules, approximately 400 to 600 A in diameter. It is, infact, residual 
smooth endoplasmic reticulum from the megakaryocyte. 
 Function :  This channel system is involved in the regulation of 
intracellular calcium transport because it has been reported to selectively bind, 
sequester, and release divalent cations after activation.  The dense tubular 
system is also the site of prostaglandin synthesis in platelets.   
Cytoskeleton  
 General Structure : The platelet cytoskeleton contains 30 to 50% of 
total platelet protein and is made up of three major structural components : an 
actin microfilament network present throughout the cytoplasm, a micro tubule 
coil localized at the platelet periphery and a membrane skeleton comprising a 
network of short actin filaments that underlies the inner surface of the plasma 
membrane.  Although they are distinct structures, interconnections between 
these elements are present. 
Structure and Function of Specific Cytoskeletal Elements 
 Actin Microfilaments : Twenty to thirty percent of total platelet protein 
is made up of actin (Pollard, 1990).  Actin exists in two forms, G-actin (actin 
monomers) and F-actin (polymerized actin).  In the unstimulated platelet, 30 to 
 40% of actin is polymerized into filaments;  the balance of actin monomers are 
prevented from polymerizing by proteins such as profilin or thymosin B4 that 
sequester monomeric actin, or by proteins that cap filaments in the intact cell, 
such as gelsolin. 
 Upon platelet activation, the proportion of filamentous actin rapidly 
increases to 60-70%.  Actin monomers polymerize onto filaments at platelet 
peripheries and bundles of new filaments form to fill developing filopodia. 
 Microtubules :  A circumferential microtubule band that supports the 
discoid form of the platelet is made up of two nonidentical subunit proteins ( 
alpha and Beta tubulin) associated with microtubule associated proteins  
(MAPs).  The 25 nm diameter microtubule coil lies adjacent to, but does not 
touch, the plasma membrane. 
 Microtubules are present primarily in their polymerized form in 
unstimulated platelets. Platelet activation results in microtubule disassembly, 
then reassembly; such alterations in the marginal microtubule bundle result in 
platelet shape changes. 
 Membrane Skeleton :  The short actin filaments of the membrane 
skeleton, which underlie the inner surface of the plasma membrane, together 
with the microtubule coil, are thought to help stabilize the platelet discoid 
shape. 
  Two major platelet membrane glycoproteins, GP IIb-IIIa and GP Ib-IX 
are associated with the membrane skeleton. 
Granules 
 Platelets contain four distinct populations of granules: alpha granules, 
dense bodies, lysosomes, and microperoxisomes.  After platelet stimulation by 
agonists, granules fuse with channels of the surface-connected canalicular 
system and extrude their contents (White, 1974).  Internal contraction is 
required for this extrusion and ultimate discharge into the surrounding medium. 
α  - Granules : 
 Structure :  α Granules are the predominant granule type in the platelet.  
The α granule has been subdivided morphologically into three distinct zones by 
electron microscopy : an electron- dense nucleoid that occupies the bulk of the 
granule, a peripheral zone of lower electron density that lies adjacent to the 
granule membrane and 1 to 6 tubular structures that reside in the electron lucent 
peripheral zone. 
 Content : B-thromboglobulin and platelet factor 4 have been localized 
to the dense nucleoid. Von Willebrand factor is present in the tubular structures 
of the granule peripheral zone.  Thrombospondin, and fibrinogen are present in 
the granular matrix.  Other proteins present in α granules include albumin, 
immunoglobin G (IgG), fibronectin, platelet derived growth factor, GPIIb-IIIa,  
Beta amyloid protein precursor, factor V, multimerin, a factor V/Va binding 
 protein, transforming growth factor β1 and a plasminogen activator similar to 
tissue plasminogen activator. 
 Proteins present on the α – granule membrane include P-selectin, GP IIb 
/ IIIa, granule membrane protein – 33 (GMP-33), CD9, platelet – endothelial 
cell adhesion molecule 1 (PECAM-1) and osteonectin. 
 Dense Bodies : 
 Structure :  Ultrastructurally, dense granules have a bull’s eye 
appearance.  They are the most electron-dense organelles in platelets. 
 Content :  The principal constituents of dense granules are a 
nonmetabolic pool of adenine nucleotides (adenosine triphosphate and 
diphosphate, ATP and ADP), PPi, calcium and magnesium and serotonin (5-
hydroytryptamine). In addition, dense bodies contain guanosine triphosphate 
and diphosphate (GTP and GDP). The dense granule membrane contains P – 
selectin and granulophysin. 
 Lysosomes : 
 Structure :  Lysosomes are small vesicles of approximately 175 to 200 
nm.   
 Content :  Lysosomes are the only platelet granules that contain acid 
hydrolases.  Platelet lysosomes contain a large variety of enzymes, including β 
hexosaminidase and β glycerophosphatase.  Lysosomal membrane glycoprotein 
 (LIMP-CD63) and lysosomal associated membrane proteins 1 and 2 (LAMP-1 
and LAMP-2) become expressed on the plasma membrane after activation. 
 Microperoxisomes : 
 Structure :  Microperoxisomes are small (90-nm) granules that are 
relatively few in number in platelets and can be demonstrated only 
cytochemically. 
 Content :  They are reactive with alkaline diaminobenzidine medium.  
The enzyme responsible for the cytochemical peroxidase activity in 
microperoxisomes is catalase. 
Coated Vesicles : 
 Structure :  Coated vesicles are 70 to 90 nm organelles  
 Content :  The polyhedral coat on the surface of these vesicles is 
composed of clathrin.  Coated pits and vesicles transfer plasma components to 
platelet granules (Behnke, 1989). 
Mitochondria : 
 Structure :  Mitochondria in platelets are similar, with the exception of 
smaller size to those in other cell types. There are approximately seven per 
human platelet.  
 Content :  Mitochondria are the site of activity for all components of the 
respiratory chain and for almost all enzymes in the citric acid cycle. 
 
 Glycogen  
 Platelets contain small particles of glycogen or masses of closely 
associated glycogen particles; these play an essential role in platelet 
metabolism. 
 
(Diagram of a human platelet displaying components visible by electron 
microscopy and cytochemistry) 
 
 
 
 
 
 
 
 PLATELET PHYSIOLOGY 
Platelet Lipids and Proteins 
Membrane Lipids 
 Phospholipids constitute 80% of the total platelet lipid, although smaller 
amounts of neutral lipids and glycolipids are also present. The five major 
phospholipids identified in human platelets are phosphatidylcholine, 
phosphatidylethanolamine, sphingomyelin, phosphatidylserine and 
phosphatidylinositol.  Almost all platelet fatty acids are esterified in 
phospholipids, leaving only trace amounts of free fatty acids.  Arachidonic acid, 
the precursor of prostaglandins and thromboxanes, is enriched in these 
phospholipids and the metabolism of arachidonic acid is critical for normal 
platelet function (Marcus, 1976). 
 Neutral lipids make up approximately 28% of total platelet lipids, the 
predominant neutral lipid being cholesterol. 
Membrane Glycoproteins : 
 Platelet membrane glycoproteins mediate a wide number of adhesive 
cellular interactions.  These glycoproteins function as receptors that can receive 
signals from outside the platelet, facilitating cell – cell interactions; binding of 
specific ligands to these receptors results in distinct platelet responses to the 
external environment. 
 
 Glycoprotein  IIb / IIIa : Glycoprotein IIb-IIIa is the principal receptor 
on the platelet plasma membrane (Philips et al, 1988).  It is a member of the 
integrin family of proteins. A Ca2+ dependent conformational change in GP 
IIb-IIIa after platelet agonist indued stimulation facilitates strong binding to 
fibrinogen and VWF resulting in cross linking of GP IIb-IIIa molecules on 
adjacent platelets and platelet aggregation. 
 Glycoprotein Ib-IX : Glycoprotein Ib mediates the interaction of 
platelets with VWF. GP Ib also functions as a binding site for thrombin. GP Ib 
is present on platelet surfaces in a 1:1 ratio with GP IX.   
 Other membrane Glycoproteins :  Membrane glycoproteins GPIa-IIa, 
GPIc – IIa, mediate platelet adhesion to collagen, fibronectin, laminin and 
vitronectin.  GP V forms a noncovalent complex with GP Ib – IX in the platelet 
membrane. PECAM-1 binds to heparin like molecules.  GPIV is a receptor for 
thrombospondin.  GP IV is also reported to bind collagen. 
Other Platelet Proteins : Other proteins presented in the platelet are platelet 
factor 4, β thromboglobulin, thrombospondin, platelet derived growth factor, 
fibronectin.   
 Platelet Factor 4:  PF4 binds heparin with high affinity and neutralizes 
its anticoagulant activity.  It exhibits a variety of activities, including the 
potentiation of platelet aggregation. 
 
 PLATELET BIOCHEMISTRY 
 The platelet has minimal ability to synthesize protein because it contains 
only low levels of RNA and lacks a nucleus.  In terms of dry weight, the 
platelet is composed of approximately 60% protein, 15% lipid and 8% 
carbohydrate.  Platelet minerals include magnesium, calcium potassium and 
zinc.  Platelets contain substantial amounts of vitamin B12, folic acid, and 
ascorbic acid. 
Platelet Energy Metabolism 
 There are several similarities between the energy metabolism of the 
platelet and that of skeletal muscle.  Both involve active glycolysis and the 
synthesis and use of large amounts of glycogen and in both, the major mediator 
of intracellular energy use in an actomyosin-like adenosine triphosphatase.  The 
platelet, like muscle, is metabolically adapted to expend large amounts of 
energy rapidly during aggregation, the release reaction, and clot retraction. 
 The major energy source for the platelet is glucose, which is rapidly 
taken up from the plasma. 
 A simplified scheme of platelet energy metabolism is shown in the 
figure below. Platelet energy is derived from the metabolism of glucose and to a 
lesser extent from the metabolism of fatty acids. Energy is provided in 
approximately equal amounts by glycolysis and the citric acid cycle. The 
 platelet energy reserve is provided by the metabolic pool of platelet nucleotides 
that is in a state of continuous turnover.  
 
(Platelet energy metabolism) 
Nucleotide Metabolism  
 Adenine nucleotides constitute 90% of free platelet nucleotides and are 
partitioned into at least two different pools, which undergo minimal 
interchange. The metabolic or cytoplasmic pool makes up 40% of total adenine 
nucleotides; it is used for the maintenance of various energy-consuming cell 
functions and is retained during platelet release. 
 The storage pool, which is present in the dense bodies, contains 
approximately two-thirds of the total platelet nucleotides, mainly in the form of 
 ADP and ATP.  It is metabolically inactive, does not rapidly incorporate 
exogenous adenine or phosphate, and equilibrates slowly with the metabolic 
pool.  Nucleotides in this pool are extruded from the platelet during the release 
reaction and cannot be replenished after release. ATP hydrolysis is required for 
conversion of G actin to F-actin. The ATP that is broken down to provide 
energy for the release reaction is not rephosphorylated, but rather is irreversibly 
degraded to hypoxanthine which diffuses out of the cell. Platelets also contain 
guanine nucleotides and uracil and cytosine pyrimidines. 
Arachidonate Metabolism  
 Arachidonic acid is released from platelet membrane phospholipids  
after stimulation by numerous agonists through the enzymatic action of 
phospholipase A2 or the combination of phospholipase C and diglyceride 
lipase.  After release, arachidonic acid can be acted on by either lipoxygenase, 
which results in the production of peroxy and hydroxy fatty acids, or by 
cyclooxygenase, which ultimately results in production of thromboxanes and 
prostaglandins. 
Platelet “Coagulation” Factors  
 Numerous platelet proteins interact with plasma coagulation proteins 
although the mechanisms by which platelet membrane component become 
reorganized and capable of functioning as a catalytic surface for plasma 
proteins are not known. 
  Several plasma coagulation factors are associated with platelets, 
including von Willebrand factor, coagulation inhibitors, and factor XIII. 
 Various substances associated with or derived from the platelet have 
been designated platelet factors 1 to 10 and denoted by Arabic numerals. The 
most important of these are PF4 and PF3. 
Platelet Factor 3 
 PF3 is required in at least two steps in the process of blood coagulation, 
namely the interaction between factors IXa and VIIIa, which results in the 
activation of factor X, as well as the interaction between factor Xa and factor 
Va which leads to the formation of prothrombinase.  These coagulation 
reactions are greatly accelerated on the platelet surface. 
 
PLATELET COUNT 
 The normal platelet count varies between  
1,50,000 – 3,50,000 / mm3 
 
ORIGIN OF PLATELETS FROM MEGAKARYOCYTES  
 The megakaryocyte is a large hematopoeitic cell, the cytoplasm of which 
fragments to form circulating blood platelets. The histogenesis of platelets from 
megakaryocytes was first described by James Wright in 1910.  The 
megakaryocytes are sessile polyploid cells which inturn descend from diploid 
 pluripotent hematopoeitic stem cells of marrow. The megakaryocytes are 
imprisoned within the sub endothelial layer of marrow sinuses by their very 
girth and volume (average 5000 femtolitres, Zhang YJ, 1991).  In these marrow 
niches, mononuclear progenitors undergo diploid doublings by the unique 
process of endomitosis.  Subsequently the polypoid megakaryocytes 
accumulate a bulky compartmentalized cytoplasmic mass with large volumes 
that at end stage maturation disintegrates abruptly to yield between 1000 and 
8000 platelets having a volume of 7-9 femto litres each (Martin et al, 1982; 
Stenberg and Levin, 1989; Corash, 1989). Megakaryocytes are suicidal 
microorgans whose mission is to proliferate and then fragment their cytoplasm 
on demand to maintain blood platelets at relatively steady levels of about 
1,50,000 – 3,50,000 / mm3. 
 Maintenance of platelet counts within this range represents a surplus of 
over 10 times that necessary to ensure routine haemostasis but provides a 
precautionary reserve for times of excess platelet loss or consumption. 
 
PLATELET LIFE SPAN, TURN OVER & REMOVAL  
 Platelet life span, based on the time required to clear labeled platelets 
from circulation, has been estimated to be 8-12 days in humans. The sites for 
platelet removal appear to be the spleen, the liver & bone marrow.  
Degranulation and loss of density and platelet constituents has not been shown 
 to decrease platelet life span indicating that the number of haemostatic 
interactions may not be a key component. 
 
PLATELET ADHESION, ACTIVATION & AGGREGATION  
 The anti thrombotic properties of intact vascular endothelium include 
potent platelet inhibitors. These inhibitors include PGI2, NO & CO which are 
labile molecules that are released by endothelial cells and act locally as 
autocoids and ADPase, an ectonucleotidase of endothelial membranes that 
breaks down platelet activating ADP. 
Adhesion  
 On vascular intimal injury, the antiplatelet properties of endothelium are 
diminished locally, while previously cryptic, thrombogenic subendothelial 
substances eg. collagen become exposed to flowing blood. Circulating platelets 
recognize sites of vascular disruption and undergo the process of adhesion to 
the site of injury.  Platelet adhesion is mediated by von willebrand factor which 
is present in the extracellular matrix of sub endothelial vessel wall.  The 
receptor of von willebrand factor on the platelet surface is localized in 
membrane glyco protein (Gp) Ib, part of the platelet membrane Gp Ib / IX-V 
complex. Platelet adhesion is also facilitated by direct binding to subendothelial 
collagen by means of specific platelet membrane collagen receptors. 
 
 Activation 
 Adherent platelets then become activated.  The platelet activation 
process results from the combined actions of several agonists that bind to their 
respective membrane receptors on adherent platelets and transmit platelet 
activating intracellular signals.  These platelet stimuli include humoral 
mediators in plasma (epinephrine, thrombin), mediator released from activated 
cells, (ADP serotonin), vessels wall extracellular matrix constituents that come 
in contact with adherent platelets (eg. collagen, von willebrand factor).  
Activated platelets then undergo release reaction during which they secrete 
prepackaged constituents of their cytoplasmic granules.  The constituents 
released from dense granules are ADP, ATP serotonin.  The constituents 
released from alpha granules are soluble adhesive proteins (fibrinogen, von 
willebrand factor, thrombospondin, fibronectin), growth factors (PDGF, TGF α, 
TGF β) procoagulants (platelet factor 4, Factor V). Simultaneously, activated 
platelets synthesize denovo and release the potent platelet activator and 
vasoconstrictor  thromboxane A2 (TX A2) 
Aggregation  
 The products of the platelet release reaction, including secreted granule 
constituents and TXA2 mediate aggregation.  During platelet aggregation 
(platelet – platelet interaction), additional platelets are recruited from 
circulation to the site of vascular injury leading to the formation of an occlusive 
 platelet thrombus. At lower shear levels (eg. in venous circulation), the 
molecular glue that mediates aggregation is fibrinogen, which can be derived 
either from plasma or from the alpha granule releasate of activated platelets.  At 
higher shear level (eg. in arteries) von willebrand factor can substitute for 
fibrinogen as the ligand of aggregation.  Fibrinogen or von willebrand factor 
binds to the specific platelet membrane receptor that are located in the Gp IIb / 
IIIa integrin complex and mediates aggregation and finally the platelet plug is 
formed. The platelet plug is anchored and stabilized by the fibrin mesh that 
develops simultaneously as the product of the coagulation cascade. 
 
PATHOGENESIS OF ACUTE MYOCARDIAL INFARCTION  
 Almost all myocardial infarction result from coronary atherosclerosis, 
generally with superimposed coronary thrombosis.  During the natural 
evolution of atherosclerotic plaques, especially those that are lipid laden, an 
abrupt and catastrophic transition may occur characterized by plaque rupture.  
After plaque rupture there is exposure of substances that promote platelet 
activation and aggregation, thrombin generation and ultimately thrombus 
formation. The resultant thrombus that is formed interrupts blood flow and 
leads to an imbalance between oxygen supply and demand and if this imbalance 
is severe and persistent, to myocardial necrosis. 
 
 PLATELET VOLUME & CARDIOVASCULAR DISEASE  
 As the initial step in the pathogenesis of acute myocardial infarction is 
plaque erosion or rupture followed by platelet adhesion, activation & 
aggregation followed by thrombus formation, platelets with more activity will 
predispose to the occurrence of myocardial infarction.  Mean platelet volume 
(MPV) correlates with platelet function and activation, whether measured as 
aggregation, thromboxane synthesis, β thromboglobulin release, procoagulant 
function or adhesion molecule expression. (Bath et al, 1996). 
 Increased platelet reactivity as well as shortened bleeding time are 
associated with increased platelet volume (Milner & Martin, 1985; Trowbridge 
& Martin, 1987). Large platelets are metabolically and enzymatically more 
active than small platelets as assessed by invitro aggregometry (Corash et al 
1977) and they have a higher thrombotic potential (Karpatkin 1972). They also 
express higher levels of procoagulatory surface proteins such as P – selectin 
(Mathur et al, 2001)  and glycoprotein III a (Pathansali et al, 2001). 
 Large platelets are denser, they produce more thromboxane A2 per unit 
volume of platelet cytoplasm and decrease bleeding time more than control 
platelets. Larger platelets aggregate more rapidly upon collagen challenge, 
release more serotonin & other granule contents and express more receptors per 
unit area (Pizzuli et al, 1998).  
 Platelet morphology and physiology are determined during or even 
before fragmentation of their precursor cell, the megakaryocyte (Rabellino et al 
1981).  Although the mechanism is still unclear, megakaryocyte ploidy seems 
to correlate closely with platelet volume (Hoffman and Long 1995).  Although 
ploidy and platelet volume are independent variables, alterations in both 
parameters usually occur in tandem (Trowbridge and Martin, 1987).  Certain 
cytokines such as Interleukin-3, thrombopoetin and in particular interleukin 6 
(IL-6) seem to have a major influence on megakaryocyte ploidy leading to the 
production of larger and more reactive platelets (Debilli et al 1993; Brown et al 
1997). Recently a frequent G/C polymorphism in the promoter region of IL-6 at 
nucleotide position (-174) has been shown to influence IL-6 serum levels 
(Fishman et al 1998).  In individuals carrying the common G allele, higher IL-6 
levels have been found compared with the levels in carriers of the C allele 
(Fishman et al 1998) 
 Large platelets are not necessarily young platelets (Martin et al, 1983) 
and there is now no convincing evidence that platelets appreciably change 
volume or density as they circulate (Penington, 1976).  
Various studies found an association between mean platelet volume and 
coronary artery disease or the occurrence of an acute myocardial infarction 
(Martin et al 1991; Pizzuli et al 1998) while others observed no effect 
(Halbmayer et al 1995) 
 Platelet volume and prognosis following acute myocardial infarction  
Hendra et al (1988) observed that all patients with severe cardiac failure 
had larger platelet volumes than patients with mild or no failure. Osuna et al 
(1998) stated that increase in mean platelet volume on admission was an 
independent risk factor for cardiac failure.  
Increased MPV was found to be an independent risk factor for recurrent 
myocardial infarction by Martin et al (1982).  
Yilmaz et al (2004) observed that in patients with dilated 
cardiomyopathy and in sinus rhythm, an increased MPV was associated with an 
increased incidence of left ventricular thrombus.  
In contrast to the above observations, Cameron et al (1983) noted that 
the increase in MPV did not appear to provide any prognostic information after 
myocardial infarction. The value in patients who died was no different from 
that of the survivors. The MPV did not correlate with the more established 
factors determining prognosis after myocardial infarction such as size of the 
infarct. 
 
AGE, SEX AND MPV 
Funiak et al (1994) observed increased MPV in patients of advanced age. 
In contrast Bancroft et al (2000) observed decreased MPV with advanced age. 
He observed no difference between genders. 
 MPV AND SMOKING 
Smokers were found to have an increased MPV (Tschope et al, 1989; 
Kario et al, 1992). 
MPV AND OTHER DISEASES 
An increased MPV was observed in diabetics compared with non 
diabetics by Sharpe et al (1993). 
Although Osuna et al (1998) observed a higher MPV in those with 
systemic hypertension, Bath et al (1996) observed no such effect. 
Ford et al (1998) observed that patients with hyperthyroidism had 
increased MPV. 
Bansal et al (2002) stated that MPV was increased in patients with 
chronic obstructive pulmonary disease and this could possibly contribute to an 
increased incidence of pulmonary embolism in these patients.  
In chronic liver disease, MPV and platelet count are decreased 
(Jorgensen et al, 1984). 
MPV AND DRUGS 
Aspirin has no effect on MPV (Pizulli et al, 1998). Recently, invitro data 
on the therapeutic effects on platelet volume of losartan, an angiotensin II 
receptor antagonist or Doxasosin, an α 1 adrenoceptor antagonist, have been 
reported (Jagroop and Mikhailidis 2001). These observation have not been 
confirmed in vivo (Jagroop and Mikhailidis 2000).  
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AIMS AND OBJECTIVES 
1. To assess the mean platelet volume in patients with acute myocardial 
infarction and to compare the results with the control group. 
2. To identify whether any association exists between mean platelet volume 
and other selected risk factors like age, sex, family history of coronary 
artery disease, smoking, systemic hypertension, diabetes mellitus.       
3. To find out the role of mean platelet volume in short term outcome after 
acute myocardial infarction .  
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 MATERIALS AND METHODS 
Setting     : Dept of Medicine and Intensive Coronary 
        Care Unit, Govt. Rajaji Hospital and  
        Madurai Medical College, Madurai 
Collaborating Department  : Dept of Cardiology, Govt. Rajaji Hospital  
   and Madurai Medical College , Madurai. 
Design of Study    : Observational prospective analytical study. 
Period of Study    : February 2005 - July 2005 
Sample Size     : 40 Patients and 20 controls  
Ethical Committee approval  : The present project was approved by the  
   ethical committee. 
Inclusion Criteria : 
Patients who had a history suggestive of acute myocardial infarction and 
whose  ECG showed ST segment elevation of >1mm in two contiguous limb 
leads or ≥ 1mm in two contiguous chest leads. 
Exclusion Criteria : 
1. Not having typical ECG changes. 
2. Presence of septicemia. 
3. Known cases of any hematological disorders.  
4. Presence of blood loss 
 5. Presence of hyperthyroidism or other endocrine disorders. 
6. Presence of chronic liver disease 
7. Presence of chronic obstructive pulmonary disease 
8. Presence of chronic renal failure on erythropoietin therapy. 
9. Past history of cerebrovascular accident. 
10. Known cases of any malignancies. 
Controls : 
 Age and sex matched subjects who did not have angina pectoris, ECG 
evidence of coronary artery disease, history of previous coronary artery disease 
and who met the above exclusion criteria were kept as controls. 
Consent : 
 Informed consent was obtained from all those who participated in the 
study or their relatives.  
Materials : 
 Thus a total of 40 cases who satisfied the inclusion and exclusion criteria 
stated above were taken up for subsequent study. 20 age and sex matched 
subjects were kept as control. 
 
 
 
 
 Definitions used for the study:  
1. Acute Myocardial Infarction: 
 A patient was considered to have acute myocardial infarction if he / she 
gave a definite clinical history suggestive of acute myocardial infarction and 
had ECG changes suggestive of acute myocardial infarction as mentioned in the 
inclusion criteria above.  
2. Diagonal earlobe crease: 
 A subject was considered to have diagonal earlobe crease if he/she had a 
crease running from anterior to posterior and from upward to downward 
direction in the lower part of the pinna as showed in the picture below. 
 
3. Smoking : 
 A subject was considered to be a smoker if he / she gave a history of 
tobacco smoking within the past 20 years. Person who had quit smoking 
completely before 20 years were not considered as smokers. 
 
Diagonal earlobe 
crease 
 4.  Systemic hypertension ; 
 A subject was considered to have systemic hypertension if he was 
already diagnosed to have systemic hypertension and was on anti hypertensive 
medication or if the systolic blood pressure during the hospital stay was found 
to be more than or equal to 140 mm Hg and / or the diastolic blood pressure 
was more than or equal to 90 mm Hg according to the JNC VII report.  
5. Diabetes Mellitus : 
 A subject was considered to have diabetes mellitus if he/she was already 
diagnosed to have diabetes mellitus or during the hospital stay was found to 
have a  
 fasting plasma glucose of > 126mg/dl  
   Or 
 2 Hour postprandial plasma glucose > 200mg/dl 
   Or 
 Symptoms of diabetes mellitus plus random blood sugar > 200 mg /dl 
6. Family history of coronary artery disease : 
 A subject was considered to have a family history of premature coronary 
artery disease if there was 
 a history of coronary artery disease in male first degree relative < 55 
years 
    Or  
 a history of coronary artery disease in female first degree relative < 65 
years  
 7. Left ventricular dysfunction : 
 Left ventricular dysfunction was divided to mild, moderate, severe 
according to ejection fraction in ECHO 
 < 29%  Severe 
 30 - 39  Moderate 
 40 - 49  Mild 
8. Short term outcome  - outcome at the end of 7 days after acute myocardial 
infarction was considered with respect to left ventricular dysfunction, left 
ventricular clot in ECHO, recurrence of angina, occurrence of arrhythmia, 
occurrence of death.       
 
Methods: 
 Selected socio-demographic, clinical and laboratory data were collected 
from the patients and controls and recorded in a proforma. (enclosed in 
Appendix – Appendix I) 
I. Socio demographic data comprised of : 
• Age 
• Sex 
• History of tobacco smoking 
• Family history of coronary artery disease 
 
 II. Clinical  data 
• Diagonal earlobe crease  
• Clinical examination.  
III Laboratory Data 
• Blood sugar 
• ECG  
• Echocardiogram 
• Platelet count 
• Mean Platelet volume 
 
ECG – 12 lead multi channel ECG was taken in all the patients 
 
ECHO – Transthoracic ECHO was done using ALOKO PRO S 100 in all the 
cases. 2-D ECHO, M- MODE ECHO was done to analyse the regional wall 
motion abnormality, presence of clot and also to assess the left ventricular 
function. Colour doppler evaluation was done to evaluate the presence of 
valvular regurgitation and also to assess the diastolic function.           
 For the above mentioned haematological parameters, 2 ml of blood was 
withdrawn by venepucture from the patients within 24 hrs of admission to the 
hospital. The venepucture site was properly cleaned and blood withdrawn and 
 collected in EDTA containing disposable tubes available in the market. The 
sample was transported immediately to a quality controlled centre where the 
sample was analysed for platelet volume. The instrument used for analysis was 
COBAS MICROS OT 18 automated haematological analyser made by 
ROCHE. 
 The instrument was started up. After start up, a pipette  appeared  from 
the instrument. Blood sample was fed to the instrument by the principal worker. 
The pipette drew the necessary amount of blood and withdrew on its own after 
taking the necessary amount of blood. From that moment a waiting time of 180 
seconds appeared  on the instrument. At the end of 180 seconds, a print out with 
the platelet count and mean platelet volume was ejected from the printer 
connected to the instrument. 
The instrument was repeatedly standardized for quality control.  
 
Conflict of interest : 
 There was no conflict of interest. 
Financial support: 
 Nil 
Limitations: 
1. Technical constraints and cost factor of the investigation have led to 
limited number of cases. 
 2. Since the lipid levels were found to be independent of mean platelet 
volume in earlier studies, it was neither considered for the present  study 
nor taken for analytical purposes.      
 
Statistical Analysis : 
 Data were entered in Microsoft excel spread sheet and analysed utilizing 
the software-Epidemiological Information Package 2002 (Epi Info 2002) - 
developed by the centre for disease control and prevention, Atlanta for World 
Health Organisation. Range, Median, Mean and Standard deviation and ‘p’ 
values were calculated using this package. Chi-square test was done to find out 
the significance of relationships between the groups. Significance was 
considered if the ‘p’ value was below 0.05. 
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 OBSERVATIONS AND RESULTS 
 The total number of subjects included in the study was 60. Among the 60 
subjects, 40 were cases and 20 were controls and their profile is furnished 
below. 
Age distribution 
 The age of the cases ranged from 35 to 75 years and that of controls 
ranged from 35 to 66 years. The mean and standard deviation for the cases were 
55.4 ± 9.1 years and those for the controls were 53.5 ± 7.3 years. There was no 
significant difference with respect to age among them. The distribution of cases 
and controls with respect to age is given in the table -1 given below. 
Table 1 
Distribution of cases and controls with respect to age 
Case Control Age Group 
No. % No. % 
< 30 - - - - 
30-39 2 5 1 5 
40-49 5 12.5 3 15 
50-59 20 50 12 60 
60 & above 13 32.5 4 20 
Total 40 100 20 100 
Range 
Median 
Mean 
S.D. 
35-75 
55 
55.4 
9.1 
35-66 
52 
53.5 
7.3 
 
‘p’= 0.4002 (not significant) 
 
 
 Sex composition 
 Among the 40 cases studied, there were 32 males and 8 females. Among 
the controls, there were 15 males and 5 females. The difference in the sex 
composition of the case and control group was not statistically significant. The 
details are furnished in table - 2 depicted below. 
Table 2 
Distribution of cases and controls in relation to gender 
Case Control Sex 
No. % No. % 
Males 32 80 15 75 
Females 8 20 5 25 
 
‘p’= 0.4476 (not significant)  
 
Diagonal earlobe crease 
 Among the 40 cases, 21 had diagonal earlobe  crease. Among the 20 
controls, 4 had diagonal earlobe crease. The diagonal earlobe crease was 
significantly present among cases than controls. The details are given in the 
table-3 given below. 
 
 
 
 Table 3 
Distribution of cases and controls with respect to the presence of diagonal 
earlobe crease 
Case Control Diagonal earlobe  
crease No. % No. % 
Yes 21 52.5 4 20 
No 19 47.5 16 80 
 
‘p’= 0.0332 (significant.) 
 
Family history of coronary artery disease 
 Among the 40 cases, 8 had a family history of coronary artery disease. 
Among the 20 controls, 4 had a family history of coronary artery disease.  The 
difference in the percentage of subjects with a family history of coronary artery 
disease was not statistically significant. The details are shown in the table 4 
given below. 
 
 
 
 
 
 Table 4 
Distribution of cases and controls with respect to family history of 
coronary artery disease 
Case Control Family History 
No. % No. % 
Yes 8 20 4 20 
No 32 80 16 80 
 
‘p’= 0.9999 (not significant) 
 
Smoking 
 Among the 40 cases, 24 had the habit of smoking. Among the 20 
controls, 7 had the habit of smoking. There were no female smokers in either 
group. There was no statistical difference in the habit of smoking between cases 
and controls. The details are depicted in the table-5 given below.  
Table 5 
Distribution of cases and controls with respect to the habit of smoking 
Case Control Smoking 
No. % No. % 
Yes 24 60 7 35 
No 16 40 13 65 
 
‘p’= 0.1205 (not significant) 
 
 
 Systemic hypertension: 
 Among the 40 cases, 8 had systemic hypertension. Among the 20 
controls, 5 had systemic hypertension. Systemic hypertension was present 
among cases and controls without any statistically significant difference. The 
details are provided in the table 6 given below. 
Table – 6 
Distribution of cases and controls with respect to the presence of 
systemic hypertension. 
 
Case Control Systemic 
Hypertension No. % No. % 
Yes 8 20 5 25 
No 32 80 15 75 
 
‘p’= 0.4476 (not significant) 
 
 
Diabetes Mellitus  
 Among the 40 cases, 11 had diabetes mellitus. Among the 20 controls, 6 
had diabetes mellitus. There was no statistically significant difference among 
cases and controls with respect to diabetes mellitus. The details are given in the 
table – 7 shown  below. 
 
 Table – 7 
Distribution of cases and controls with respect to the presence of diabetes 
mellitus. 
Case Control Diabetes 
Mellitus No. % No. % 
Yes 11 27.5 6 30 
No 29 72.5 14 70 
 
‘p’= 0.9193 (not significant) 
 
History of previous Myocardial Infarction 
 Among the 40 cases, 8 had a history of previous myocardial infarction. 
The details are given in Table – 8 given below. 
Table  - 8 
Distribution of cases with respect to the presence of history of previous 
myocardial infarction. 
Case Previous MI 
No. % 
Yes 8 20 
No 32 80 
 
 Aspirin intake 
Among the 40 cases, 11 were taking aspirin.  The details are given in the 
table – 9 given below.  
Table – 9 
Distribution of cases with respect to the presence of aspirin intake 
Case On Aspirin 
No. % 
Yes 11 27.5 
No 29 72.5 
 
Platelet Count 
 The mean platelet count of the cases was 2.05 ± 0.46 lakhs/mm3. 
The mean platelet count of the controls was 2.24 ± 0.39 lakhs / mm3. There was 
no significant difference in the platelet count between the cases and controls.     
The details are given in table – 10 furnished below.  
 
 
 
 
 
 
  
Platelet Count in Cases and Controls 
 
 
2.05
2.24
1.95
2
2.05
2.1
2.15
2.2
2.25
Pl
a
te
le
t C
o
u
n
t i
n
 
La
ks
hs
 
/ m
m
3
Case Control
 
 
 
 
 
 
 
 
 
 Table – 10 
Platelet count in cases and controls 
Case Control Platelet Count 
No. % No. % 
Upto 1.5 5 12.5 - - 
1.5 – 2.49 30 75.0 16 80 
2.5 – 3.49 5 12.5 4 20 
3.5 & above - - - - 
Total 40 100 20 100 
Range 
Median 
Mean 
S.D. 
1.2 – 3.19 
2.02 
2.05 
0.46 
1.69-3.06 
2.13 
2.24 
0.39 
 
‘p’= 0.1241(not significant) 
 
Mean Platelet Volume   
The mean platelet volume of the cases ranged from 8.8 to 10.8 
femtolitres. The mean platelet volume of the controls ranged from 7.7 to 9.4 
femtolitres. The mean ± S.D of the cases was 9.8 ± 0.56 femtolitres. The mean 
± S.D of the controls was 8.2 ± 0.43 femtolitres. A comparative analysis of the 
mean platelet volumes between the cases and controls showed a statistically 
significant difference. The details are given in the table – 11 given below  
 MPV in Cases and Controls  
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Wall Distribution of Myocardial Infarction 
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 Table – 11 
MPV in cases and controls 
MPV Case Control 
Range 
Median 
Mean 
S.D. 
8.8-10.8 
9.8 
9.8 
0.56 
7.7-9.4 
8.1 
8.2 
0.43 
‘p’= 0.0001 (significant) 
Wall Distribution of Myocardial Infarction  
 The wall distribution of myocardial infarction is shown in table – 12 
given below. 
Table – 12 
Wall Distribution of Myocardial Infarction 
Wall Distribution  No. % 
AWMI 
AWMI + LWMI 
IWMI 
IWMI + LWMI 
IWMI + PWMI 
IWMI + PWMI + RVMI 
IWMI + RVMI 
LWMI 
12 
7 
3 
1 
7 
6 
3 
1 
30 
17.5 
7.5 
2.5 
17.5 
15 
7.5 
2.5 
 
 
Anterior Wall was found to be the most involved (30%). 
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 RELATIONSHIP BETWEEN MPV AND OTHER PARAMETERS   
Table – 13 
Relationship between Age & MPV 
MPV Values Age Group 
Range Median Mean S.D. 
< 30 - - - - 
30-39 9.3 – 10.1 9.7 9.7 0.57 
40-49 9 – 10.4 9.9 9.76 0.56 
50-59 8.6 – 10.6 9.7 9.67 0.51 
60 & above 8.8 – 10.8 10.1 10.13 0.59 
‘p’ =  0.121 (not significant) 
 The relationship between age and MPV is not statistically significant. 
 
Table – 14 
Relationship between Sex & MPV 
 The mean MPV for males was 9.81 ± 0.56 femtolitres. The mean MPV 
for females was 9.9 ± 0.61 femtolitres. MPV was found to be independent of 
gender.  
MPV Values Sex 
Range Median Mean S.D. 
Males (32) 8.6 – 10.8 9.85 9.81 0.56 
Females (8) 9.1 – 10.8 9.75 9.9 0.61 
‘p’ =  0.9729 (not significant) 
 
 
 Table – 15 
Relationship between Diagonal earlobe crease and MPV 
MPV Values Diagonal earlobe 
crease Range Median Mean S.D. 
Yes (21) 8.8 – 10.8 9.9 10.01 0.53 
No (49) 8.6 – 10.8 9.6 9.63 0.55 
‘p’ = 0.0376 (significant) 
There exists a statistically significant relationship between diagonal 
earlobe crease and increased MPV values.  
 
 
Table – 16 
Relationship between family history of coronary artery disease and  MPV 
MPV Values Family History 
Range Median Mean S.D. 
Yes (8) 8.8 – 10.8 9.9 9.89 0.6 
No (32) 8.6 – 10.8 9.8 9.82 0.56 
 
‘p’ =  0.709 (not significant) 
The relationship between family history of coronary artery disease and 
MPV was not significant. 
 Table – 17 
Relationship between smoking and MPV 
MPV Values Smoking 
Range Median Mean S.D. 
Yes (24) 8.8 – 10.8 9.95 9.87 0.49 
No (16) 8.6- 10.8 9.75 9.77 0.67 
 
‘p’ =  0.438 (not significant) 
The mean MPV among smokers was 9.87± 0.49 femtolitres. The mean 
MPV among non smokers was 9.77 ± 0.67 femtolitres. Even though the mean 
MPV was higher among the smokers, it was not statistically significant. 
 
Table – 18 
Relationship between systemic hypertension & MPV 
MPV Values Systemic Hypertension 
Range Median Mean S.D. 
Yes (8) 9.1 – 10.8 9.95 9.95 0.6 
No (32) 8.6 – 10.8 9.8 9.8 0.56 
‘p’ =  0.4658 (not significant) 
There was no significant relationship between systemic hypertension and 
MPV. 
 Table – 19 
Relationship between Diabetes Mellitus & MPV 
MPV Values Diabetes Mellitus 
Range Median Mean S.D. 
Yes (11) 9 – 10.8 9.7 9.78 0.53 
No (29) 8.6 – 10.8 9.9 9.85 0.58 
 
‘p’ =  0.5948 (not significant) 
The relationship between diabetes mellitus and MPV was not 
statistically significant. 
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 Table – 20 
Relationship between history of previous myocardial infarction and MPV. 
MPV Values Previous MI 
Range Median Mean S.D. 
Yes (8) 9.5 – 10.8 10.25 10.2 0.48 
No (32) 8.6 – 10.8 9.75 9.74 0.55 
‘p’ =  0.0435 (significant) 
The mean MPV in cases with a previous history of myocardial infarction 
was 10.2±0.48 femtolitres. The mean MPV in cases without a previous history 
of myocardial infarction was 9.74±0.55 femtolitres. A significant difference 
was observed between the cases with previous myocardial infarction and those 
without previous myocardial infarction. 
Table – 21 
Relationship between Aspirin intake and MPV 
MPV Values On Aspirin 
Range Median Mean S.D. 
Yes (11) 8.8 – 10.8 9.8 9.91 0.66 
No (29) 8.6 – 10.8 9.8 9.8 0.53 
‘p’ =  0.5739 (not significant) 
The relationship between aspirin intake & MPV was not statistically 
significant. 
 Table – 22 
Relationship between platelet count & MPV 
MPV Values Platelet Count  
(in lakhs / mm3) Range Median Mean S.D. 
Upto 1.5 (5) 9.2-10.4 9.9 9.88 0.44 
1.5 – 2.49 (30) 8.6-10.8 9.8 9.86 0.6 
2.5 – 3.49 (5) 9.1-10.1 9.4 9.58 0.44 
3.5 & above - - - - 
‘p’ = 0.5616 (not significant) 
There was no significant relationship between platelet count and MPV. 
Table – 23 
Relationship between ejection fraction & MPV 
MPV Values Ejection Fraction 
Range Median Mean S.D. 
< 29 (2) 10.6-10.8 10.7 10.7 0.14 
30-39 (3) 9.7-10.4 10.1 10.07 0.35 
40-49 (22) 8.6-10.4 9.8 9.78 0.61 
50 & above (13) 8.8-10.4 9.8 9.73 0.44 
 
‘p’ =  0.1488 (not significant) 
 The mean MPV in cases with ejection fraction ≤ 29 was 10.7 ± 0.14 
femtolitres. Although this value was higher than the other groups with higher 
ejection fractions it was not statistically significant. 
 
 
 Table – 24 
Relationship between the presence of LV Clot & MPV 
MPV Values Clot 
Range Median Mean S.D. 
Yes  (2) 10.4-10.8 10.6 10.6 0.28 
No (38) 8.6-10.8 9.8 9.8 0.55 
‘p’ =  0.536 (not significant)  
 
 
Table – 25 
Relationship between recurrence of angina and MPV 
MPV Values Recurrence of angina 
Range Median Mean S.D. 
Yes  (2) 9.8-10.8 10.3 10.3 0.7 
No (38) 8.6-10.8 9.8 9.8 0.55 
 
‘p’ = 0.2898 (not significant) 
Although the mean MPV in cases with recurrence of angina was higher 
than the rest, it was not statistically significant. 
 
 
The mean MPV in cases with the presence of LV clot was observed 
to be higher than those without LV clot, but there was no statistical 
significance. 
 Table – 26 
Relationship between survival without complications and MPV 
MPV Values Survival  
without complications Range Median Mean S.D. 
Yes  (18) 8.6-10.8 9.85 9.83 0.54 
No (22) 8.8-10.8 9.8 9.83 0.59 
 
‘p’ = 0.87 (not significant) 
The relationship between survival without complications and MPV was 
not statistically significant. 
Table – 27 
Relationship between occurrence of death and MPV 
MPV Values Death 
Range Median Mean S.D. 
Yes (4) 9-10.8 9.45 9.68 0.83 
No (36) 8.6-10.8 9.85 9.85 0.54 
 
‘p’ =  0.4692 (not significant) 
The MPV of the patients who died was not statistically significantly 
different from those who survived. 
 
  
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 DISCUSSION 
 Myocardial infarction is a major cause of morbidity and mortality in 
developed countries and is becoming a major problem in developing countries 
like India. Endogenous and exogenous risk factors like smoking, 
hypercholesterolemia, diabetes mellitus and systemic hypertension significantly 
increase the individual risk for myocardial infarction. However they only 
explain a part of the cases and there may be other relevant risk factors which 
need to be identified. Large platelets are more reactive, produce more 
thrombotic factors (Martin et al, 1983) and aggregate more easily (Haver et al, 
1981). 
 Endler et al (2002) stated that mean platelet volume (MPV) is an 
independent risk factor for myocardial infarction. Similar observations were 
made by Martin et al (1983), Cameron et al (1983). But all these are studies 
conducted in the west with healthy western people serving as controls. So in 
this study an attempt was made to find out if any association existed between 
the platelet size and the occurrence of myocardial infarction among Indian 
population as reports are scanty. 
 In the study, the ages of the cases ranged from 35 to 75 years . The mean 
was 55.4 ± 9.1 years. The maximum number of cases i.e., 20 cases fell in the 
age group 50-59 years. This comes to 50% of the total cases. This pattern 
 corresponds to the pattern reported in India, which is as follows. Coronary 
artery disease appears a decade earlier compared with the age incidence in 
developed countries and the peak period is attained between 51-60 years. (Park 
K, 2005). 
 In the present study the relationship between age and MPV was not 
statistically significant where as Funiak et al (1994) found that MPV was 
significantly increased in patients of advanced age and it was statistically 
significant. But Bancroft et al (2000) stated that MPV decreases with age. But 
our study did not conform to any of the observations made by the above two 
workers.  
 Among the 40 cases, there were 32 males (80%) and 8 females (20%). 
Before menopause, women have a lower age adjusted incidence and mortality 
for coronary heart diseases than men. Gender specific incidence rates converge 
after menopause, suggesting a major role for estrogen in delaying progression 
of atherosclerosis. Much of this effect results from beneficial action of estrogen 
on lipid fractions. Estrogen reduces LDL - C by 10-15% while increasing  
HDL - C. 
 In the present study MPV was independent of genders. This is in parallel 
with the observation made by Bancroft et al (2000).  
 Among the 40 cases of myocardial infarction, 21 had the presence of 
diagonal earlobe crease (Frank’s sign), while only 4 among the 20 controls had 
 this. Lichstein et al (1976) stated that, ninety percent of patients over age 50 
with significant triple vessel coronary disease had a deep ear lobe crease and 
that a unilateral ear crease was found to be associated with an intermediate 
degree of coronary obstruction. The ear lobe crease should be considered a 
strong and independent risk factor for coronary artery disease and NOT 
diagnostic for the presence of coronary artery disease, for which it is only 60% 
sensitive (Elliot et al, 1991). 
 Among the cases, those with diagonal earlobe crease were found to have 
a significantly higher MPV when compared to those without. Whether diagonal 
earlobe crease can be considered as an external marker for increased MPV 
needs to be further investigated.          
 8 cases among the 40 cases had a family history of coronary heart 
disease. Family history of premature coronary heart disease is a risk factor for 
coronary heart disease. Family history of premature coronary heart disease is 
considered positive if there is coronary heart disease in male first degree 
relative <55 years or if there is coronary heart disease in female first degree 
relative < 65 years.  
In the present study no significant relationship was observed between a 
family history of coronary artery disease and MPV.  
Among the 40 cases, 24 were smokers (60%) and among the 20 controls 
7 were smokers (35%). Although this shows an increased prevalence of 
 smoking habit among those with coronary heart disease, it was not statistically 
significant. It has been calculated that in countries where smoking has been a 
wide spread habit, it is responsible for 25% of coronary heart disease deaths 
under 65 years of age (WHO 1979). A uniquely human habit, smoking has been 
identified as a major coronary risk factor. The small sample size may be the 
reason why a statistical significance was not observed between the cases and 
controls with respect to smoking.  
 Although the MPV was higher among smokers compared to controls, the 
relationship was not statistically significant. Tschope et al (1989) and Kario et 
al (1982) in separate studies found smokers to have an increased MPV. But 
Kishk et al (1985) observed no relation between smoking and MPV. Our 
finding runs in parallel with that of Kishk et al (1985).    
 Among the myocardial infarction patients 8 had systemic hypertension 
(20%). In a study conducted by Gupta et al (2001) on myocardial infarction, the 
prevalence of systemic hypertension in myocardial infarction patients was 
found to be 32.6%.  
In the present study no statistical relationship was observed between 
systemic hypertension and MPV. Bath et al (1996) also observed the same in  
their study. In contrast, Osuna et al (1998) observed a higher MPV in those with 
systemic hypertension.       
  11 patients (27.5%) in the present study had diabetes mellitus. This is 
similar to the prevalence of diabetes mellitus in myocardial infarction patients 
in the study by Gupta et al (2001), which was 21%. 
 The MPV in patients with diabetes mellitus did not vary from those 
without diabetes mellitus. Sharpe et al (1993) stated that MPV was significantly 
increased in diabetic subjects compared with non diabetics. They stated that 
since the platelet size is a determinant of platelet function, with larger platelets 
being more reactive per unit volume, the platelets might play a part in the micro 
and macro vascular complications of diabetes mellitus. Osuna et al (1998) also 
observed a higher MPV with diabetes mellitus. The fact that in our study, no 
relationship was observed may be due to the small sample size.  
Of the 40 patients studied, 8 had a previous attack of myocardial 
infarction.         
 The MPV in patients with a previous history of MI was significantly 
higher than those without a previous history of MI. Martin et al (1991) stated 
that increased MPV is an independent risk factor for recurrent MI.  Osuna et al 
(1998) also stated that a large MPV was associated with a higher prevalence of 
prior MI. This finding of the present study runs in parallel with the observation 
made by the earlier workers.  
 In the present study 4 out of those with a previous history of myocardial 
infarction were on aspirin. 7 more patient were also on aspirin for angina. Thus 
 a total of 11 patients were taking aspirin. The MPV in patients on aspirin and in 
those not on aspirin was not statistically different Pizulli et al (1998) also stated 
that aspirin has no effect on platelet volume. However similar studies in larger 
population are required to confirm this observation.       
         The mean platelet count of the cases was 2.05± 0.46 lakhs / mm3 and 
that of the controls was 2.24± 0.39 lakhs / mm3. Although the mean platelet 
count among the cases was less compared to the controls it was not statistically 
significant. Senaran et al (2001) stated that patients with acute myocardial 
infarction had increased platelet counts. Their observation was that in patients 
with myocardial infarction, there was increased thrombopoeitin levels. 
Increased thrombopoeitin levels may increase both platelet counts and platelet 
size, resulting in haemostatically more active platelets, which may contribute to 
the development and progression of coronary artery disease. However the 
observation by Senaran et al (2001) was in contrast to that of Cameron et al 
(1983) as they noticed that patients with acute myocardial infarction had a 
reduced platelet count compared to the controls. They suggested that reduced 
platelet count may be due to the consumption of platelets at the thrombus site. 
But in our study, there was no significant difference in the platelet counts 
between the case and the control groups.  
 There was no significant relationship between platelet count and MPV in 
our study. There are contrasting views regarding this aspect. Senaran et al 
 (2001) observed both an increased platelet count and MPV in patients with 
myocardial infarction as stated above. But Camaron et al (1983) observed a 
reduced platelet count and higher MPV in patient with myocardial infarction. 
They stated that the reduced platelets count may be due to the consumption of 
platelets at the thrombus site as stated above. The observations in our study did 
not run in  parallel with the findings of the above two workers.  
The MPV of the cases ranged from 8.8 to 10.8 femtolitres with a mean 
of 9.8 ± 0.56 femtolitres. The MPV of the controls ranged from 7.7 to 9.4 
femtolitres with a mean of 8.2±0.43 femtolitres. The difference between the two 
was statistically significant.  
 Previous studies on MPV and myocardial infarction have given different 
observations  
 Halbmayer et al (1995) stated that MPV did not differ significantly 
between patients and controls in their study. In contrast to this Cameron et al 
(1983) found an increased mean platelet volume among those with acute 
myocardial infarction compared to controls. Similar findings was observed by 
Martin et al (1983) in their study. Large platelets are denser, they produce more 
thromboxane A2 per unit volume of platelet cytoplasm. Larger platelets 
aggregate more rapidly upon collagen challenge, release more serotonin and 
other granule contents and express more receptors per unit area (Pizzuli et al, 
 1998). So an increased MPV, as an indicator of larger, more reactive platelets, 
may represent a risk factor for myocardial infarction (Endler et al, 2002). 
 One question is that, does the increase in platelet volume occur before 
the myocardial infarction or does it occur as a response to the platelet 
consumption in myocardial infarction.  Martin et al (1983) who did a study on 
mean platelet volume in acute myocardial infarction measured platelet volume 
within 12 hours of admission to hospital and then later at 6 weeks. They stated 
that mean platelet volume was increased before myocardial infarction occurred 
for the following reasons. They  said that the increase in volume seen within the 
first 12 hours of admission suggested that the increase was present before 
infarction, as the life span of the platelet is about 8 days. More than 90% of the 
platelet population whose distribution was measured after myocardial infarction 
were circulating before the vascular occlusion occurred. They also observed 
that the increase in MPV persisted six weeks after discharge from hospital, 
when the infarct would have been largely healed. This also supported the view 
that platelet volume was chronically larger in the infarct group.  
 Further proof that the increase in mean platelet volume occurs before 
acute myocardial infarction is got from the study conducted by Endler et al 
(2002). They evaluated mean platelet volume in patients presenting with acute 
myocardial infarction and in patients with a history of previous myocardial 
infarction which had occurred upto 37 years before the study. They compared it 
 with those without myocardial infarction. They found out that the MPV was 
significantly raised in those with acute MI and in those with a history of 
previous myocardial infarction when compared to those without myocardial 
infarction. They also observed that there was no significant difference in the 
MPV between those with acute myocardial infarction and those with a history 
of previous myocardial infarction. This showed that the time interval between 
the occurrence of MI and the estimation of MPV did not influence the value of 
MPV. This further adds to the proof that raised MPV precedes the occurrence 
of MI. 
 O’Malley et al (1995) conducted a similar study of MPV estimation in 
stroke patients. They estimated MPV in stroke patients within 48 hours of 
admission and also at 6 months later and compared it with controls. They found 
that MPV was significantly raised in stroke patients compared to controls. They 
suggested that the changes in MPV might have preceded the vascular event and 
is unlikely to be due to platelet consumption at the infarct site. They said that 
since the average life span of the platelets is about 8 days, the elevated MPV 
seen within the first 48 hours after stroke represented platelets released before 
infarction. Further more it was unlikely that platelet consumption due to the 
localized thrombosis would affect peripheral venous estimation of platelet 
variables. They further stated that since there was no difference in MPV 
between large cortical strokes and small lacunar infarcts, it was unlikely that 
 platelet consumption at the thrombus site would affect the peripheral venous 
estimation of platelet variables. They also added that, the fact that the observed 
increase in MPV had remained unchanged in post stroke survivors was further 
evidence that changes in MPV were likely to have preceded the acute event.  
 From these, we can assume that the increased MPV might have occurred 
before acute myocardial infarction and unlikely to have occurred after the 
event.  
 Although the highest MPV of 10.7 femtolitres was observed in those 
with the least ejection fraction i.e., < 29%, there was no statistical significance. 
Hendra et al (1988) stated that all patients with severe cardiac failure had larger 
platelet volumes than patients with mild or no failure. Osuna et al (1998) also 
observed that an increased platelet volume was related to a higher risk of 
cardiac failure. But our study showed only non significantly higher platelet 
volumes in those with severe left ventricular dysfunction.  
 Although the mean MPV in cases with the presence of left ventricular 
clot was higher than those without left ventricular clot, it was not statistically 
significant. Yilmaz et al (2004) observed that in patients with dilated 
cardiomyopathy and in sinus rhythm, an increased MPV was associated with an 
increased incidence of left ventricular thrombus. But the number in one 
subgroup is too small to reach a logical conclusion.  
  The mean MPV in cases with recurrence of angina was 10.3 which was 
higher than the rest. But it was not statistically significant. Martin et al (1991) 
observed that the MPV was greater in those with a recurrent ischemic event. 
Osuna et al (1998) also observed that an increased MPV was associated with a 
non significant higher rates of ischemic events during the recovery phase of 
acute myocardial infarction. Here also the small number in one subgroup 
prevent us from reaching a logical conclusion.  
 There was no significant difference in MPV among the group that 
survived without complications and the rest. The 4 patients who died did not 
have a statistically significant higher MPV compared to the rest. 
 According to Cameron et al (1983), the increase in MPV did not appear 
to provide any prognostic information during the period of study. They 
observed that the values in patients who died was no different from that of the 
survivors. They observed that MPV did not correlate with more established 
factors determining prognosis after infarction such as the size of the infarct. 
Their observations were in contrast to the observations by Hendra J et al(1988), 
Osuna et al (1998) and Martin et al (1991) which have been cited above.  
LIMITATIONS 
1. The subgroup analysis could not be undertaken successfully as the 
number becomes small among sub groups. Hence statistically adequate 
 numbers should be included in future studies to arrive at valid 
conclusions. 
2. Mathematical analysis by way of log probability studies among platelet 
volume and platelet count was not attempted. 
 
AREAS OF FURTHER WORK 
1. MPV studies in other thrombotic episodes. 
2. Follow up study of MPV after the onset of clinical events and finding 
out the association between MPV and platelet count by apply the log 
probability formula. 
3. Platelet volume studies among patients on losartan and doxasosin.  
4. Invitro studies on factors contributing for thrombomegaly in order to 
introduce interventional measures. 
5. Studies to find out the physiological mechanisms which regulate MPV 
within the megakaryocyte.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
CONCLUSION 
 
 
 
 
 
 
 
 
 
 CONCLUSION 
• MPV was significantly elevated in patients with acute myocardial 
infarction (9.8 ± 0.56 femtolitres) when compared with controls (8.2 ± 
0.43 femtolitres).  
• The presence of diagonal earlobe crease among cases was significant 
compared to controls.  
• MPV in patients with acute myocardial infarction was found to be 
independent of age, sex, family history of coronary artery disease, 
smoking, systemic hypertension and diabetes mellitus. 
• MPV was higher with the presence of diagonal earlobe crease among 
cases.  
• A significantly higher MPV was noted in patients with a history of 
previous myocardial infarction.  
• Aspirin was not found to have any significant association with MPV. 
• There was no correlation between platelet count and MPV. 
• No correlation was found between MPV and short term outcome after 
myocardial infarction.  
 
 
 
  
 
 
 
 
 
 
 
SUMMARY 
 
 
 
 
 
 
 
 
 
 
 SUMMARY 
 The study ‘Mean Platelet Volume in acute myocardial infarction’ was 
done to assess the relationship between mean platelet volume (MPV) and the 
occurrence of acute myocardial infarction and to find out its association with 
the risk factors and short term prognosis after acute myocardial infarction.  
 With rigid criteria 40 patients were selected carefully and were evaluated 
on social, clinical and laboratory aspects after institutional ethical clearance 
with an informed consent. 20 subjects were taken as controls. The data were 
entered in Microsoft Excel spread sheet and analysed statistically. 
 There were 32 males and 8 females in the patient group. There were 15 
males and 5 females in the control group. The mean age of the patient group 
was 55.4 ±  9.1 years and that of the control group was 53.5 ± 7.3 years (p value 
0.4002 - not statistically significant). The diagonal earlobe crease was present 
in 21 patients and in 4 controls. The difference was statistically significant (p 
value 0.0332). The prevalence of family history of coronary artery disease, 
smoking, systemic hypertension, diabetes mellitus were noticed in both groups 
without statistical significance. The mean platelet count in cases was 2.05 ± 
0.46 lakhs/mm3 and that of the controls was 2.24 ± 0.39 lakhs/mm3 (p = 0.1241 
- not statistically significant). The MPV of the patients ranged from 8.8 to 10.8 
femtolitres and that of the controls ranged from 7.7 to 9.4 femtolitres. The mean 
 ± SD of the patients was 9.8 ± 0.56 femtolitres and that of the controls was 8.2 
± 0.43 femtolitres. This was statistically significant (p=0.0001). There was no 
significant relationship between age, sex, family history of coronary artery 
disease, smoking, systemic hypertension, diabetes mellitus, platelet count and 
MPV. MPV was higher among those with diagonal earlobe crease (p=0.0332-
significant). The mean MPV in patients with a history of previous myocardial 
infarction was 10.20 ± 0.48 femtolitres and in those without a previous history 
of myocardial infarction was 9.74 ± 0.55 femtolitres which was statistically 
significant (p=0.0435). MPV was found to be independent of aspirin intake 
(p=0.5739-not significant). There was no correlation between MPV and short 
term prognosis like left ventricular dysfunction and death. 
 From the present study, it is concluded that MPV is significantly raised 
in patients with acute myocardial infarction compared to controls. MPV is 
independent of risk factors like age, sex, family history of coronary artery 
disease, smoking, systemic hypertension, diabetes mellitus. MPV is 
significantly higher in patients with a previous history of myocardial infarction. 
MPV does not correlate with short term outcome after acute myocardial 
infarction. Further research is required into the role of platelet volume in 
myocardial  infarction  pathology, outcome and most importantly, in individuals  
 
at risk of myocardial infarction. Whether MPV becomes a routinely requested 
test remains to be seen. 
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 APPENDIX I 
PROFORMA 
MEAN PLATELET VOLUME IN ACUTE MYOCARDIAL 
INFARCTION 
Case No : 
Name  : 
Age  : 
Sex  : 
Occupation  : 
IP No  : 
DOA  : 
DOD  : 
 
Diagonal ear crease  : Yes / No 
Family History of CAD : Yes / No 
Smoking    : Yes / No 
Systemic Hypertension  : Yes / No  If yes, under regular Rx? Yes / No 
Diabetes mellitus  : Yes / No If yes, under regular Rx? Yes / No 
 
HISTORY 
 
Chronic stable angina : Yes / No 
Unstable angina  : Yes / No 
Previous MI   : Yes / No 
On aspirin    : Yes / No 
Time of onset of pain :  
Time of admission   : 
Thrombolysed  : Yes / No 
Time of thrombolysis : 
 
EXAMINATION : 
 
Pulse     : 
BP     : 
S3     : 
Crackles < 50% of lung fields  : Yes / No 
Crackles > 50% of lung fields : Yes / No 
Cardiogenic shock   : Yes / No 
Killip class    : I II III IV 
 INVESTIGATIONS : 
 
Blood sugar    : 
Urea    : 
Creatinine   : 
S.CPK   : 
S.CPK MB   : 
Platelet count   : 
Mean platelet volume : 
 
ECG 
 
 
 
ECHO 
 1. RWMA   : Yes / No if yes, wall 
 2. Ejection fraction   : 
 3. Diastolic dysfunction  : Yes / No 
 4. Clot   : Yes / No 
 
OUTCOME 
 
Survived without complications 
Survived with complications 
   Cardiac failure 
   Recurrence of angina 
   Reinfarction 
   Arrhythmias 
   
Death 
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 APPENDIX II 
 
MASTER CHART 
CASES 
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1 MI 45 1 1 2 2 2 2 2 2 1.45 9.9 1 2 2 2 2 43 2 2 2 2 2 
2 MI 75 2 2 2 2 1 2 1 2 2.13 9.8 1 2 2 2 2 43 2 2 2 2 1 
3 MI 53 1 1 2 1 2 2 2 2 1.92 10.6 1 2 2 2 2 28 2 2 2 2 2 
4 MI 55 1 2 2 2 2 2 2 2 2.45 8.6 1 2 2 2 2 45 2 2 2 1 2 
5 MI 42 1 2 2 1 2 2 2 2 2.14 9.4 1 2 2 2 2 50 2 2 2 1 2 
6 MI 51 1 1 1 1 2 2 2 2 1.74 10 1 2 2 2 2 51 2 2 2 1 2 
7 MI 56 1 1 1 1 1 2 1 1 2.14 10.4 1 2 2 2 2 44 2 2 2 1 2 
8 MI 55 1 2 2 1 2 1 2 2 3.06 10 1 2 2 2 2 42 2 2 2 2 2 
9 MI 67 1 1 2 1 2 2 2 2 2.08 10.1 2 2 1 2 2 34 2 2 1 2 2 
10 MI 65 1 2 2 2 2 2 1 1 2 10.8 2 2 1 2 1 21 2 2 1 2 1 
11 MI 52 1 2 1 2 2 1 2 2 1.67 9.5 1 1 2 2 2 42 2 2 2 2 2 
12 MI 65 1 1 2 1 2 2 2 1 2.36 10.4 2 2 1 1 1 50 2 2 2 1 2 
13 MI 60 1 2 2 1 2 2 2 2 1.69 9.9 2 2 1 1 1 60 2 2 1 2 2 
14 MI 53 1 2 2 1 2 1 2 2 1.73 9.7 2 2 1 1 2 48 2 2 2 1 2 
15 MI 53 2 2 2 2 1 2 2 2 2.27 9.1 2 2 1 2 1 46 2 2 1 2 1 
16 MI 50 2 1 2 2 2 1 2 2 2.03 9.7 2 2 1 1 2 60 2 2 1 2 2 
17 MI 65 1 1 1 1 2 2 2 1 1.81 8.8 1 2 2 2 2 50 2 2 2 2 2 
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18 MI 52 1 1 2 1 1 2 2 2 1.2 9.2 1 1 2 2 2 60 2 2 2 2 2 
19 MI 65 1 2 2 1 2 1 2 2 1.21 10.1 2 2 1 1 1 50 2 2 2 1 2 
20 MI 58 1 2 2 1 2 2 2 2 2.24 9.1 2 2 1 1 1 48 2 2 2 2 2 
21 MI 56 1 1 1 1 2 2 1 2 2.65 10.1 1 1 2 2 2 59 2 2 2 2 2 
22 MI 69 1 1 2 1 2 2 2 1 1.7 9.7 1 1 2 2 2 42 2 2 2 2 2 
23 MI 36 1 2 2 1 2 2 2 2 1.75 10.1 2 2 1 1 2 52 2 2 2 1 2 
24 MI 65 2 1 2 2 2 2 2 2 2.32 9.9 2 2 1 2 1 48 2 2 2 1 2 
25 MI 60 2 1 2 2 1 1 1 2 1.85 10.8 2 2 1 2 2 40 1 2 2 2 2 
26 MI 50 1 1 2 1 1 2 1 1 2 9.8 2 1 2 2 2 46 2 1 2 2 2 
27 MI 50 2 2 2 2 2 2 2 2 2.79 9.4 1 1 2 2 2 52 2 2 2 1 2 
28 MI 55 1 2 2 1 1 2 1 2 1.33 10.4 2 2 1 1 2 36 1 2 2 1 2 
29 MI 50 1 2 2 1 2 2 2 2 1.78 9.6 2 2 1 1 2 55 2 2 2 1 2 
30 MI 45 1 2 2 2 2 1 2 1 2.43 9 1 1 2 2 2 48 2 2 2 2 1 
31 MI 53 1 2 2 2 2 1 2 2 3.19 9.1 2 2 1 1 1 46 2 2 2 1 2 
32 MI 50 1 1 2 2 2 1 2 1 1.8 9.8 1 1 2 2 2 52 2 2 2 1 2 
33 MI 56 1 1 2 1 2 1 1 1 2.46 9.5 1 2 2 2 2 48 2 2 2 2 2 
34 MI 35 1 2 2 1 2 2 2 2 2.74 9.3 1 2 2 2 2 43 2 2 2 1 2 
35 MI 55 2 1 1 2 2 2 2 2 1.93 9.7 2 2 1 1 2 30 2 2 2 2 2 
36 MI 48 1 1 2 2 2 1 2 2 2.2 10.4 1 2 2 2 2 42 2 2 2 2 2 
37 MI 60 1 1 1 1 2 2 2 1 2.1 10.8 2 2 1 2 2 40 2 2 2 1 2 
38 MI 70 1 1 1 1 2 2 2 2 1.38 9.8 2 2 1 1 2 46 2 2 2 1 2 
39 MI 45 1 2 2 1 1 2 2 1 2.12 10.1 2 1 1 2 2 48 2 2 2 1 2 
40 MI 70 2 1 2 2 2 2 2 2 2 10.8 2 2 1 1 1 40 2 1 2 2 2 
 
Sex  1-Male, 2-Female    Other Parameters  1-Yes, 2-No 
 CONTROLS 
 
Sl.No GROUP AGE SEX D.E.CREASE FAMILY 
HIST. 
SMOKING SYS.H.T. DIA.MELL. PLAT.COUNT MPV 
1.  CONTROL 50 1 2 2 1 2 2 2.14 8.3 
2.  CONTROL 58 1 1 1 2 2 2 2.88 8 
3.  CONTROL 35 1 2 2 1 2 2 2.45 9.4 
4.  CONTROL 52 2 2 2 2 1 2 2 7.8 
5.  CONTROL 48 1 2 1 2 2 2 1.8 8 
6.  CONTROL 60 2 2 2 2 1 1 3.06 7.9 
7.  CONTROL 56 1 2 2 1 2 2 2.62 8.9 
8.  CONTROL 64 1 1 2 2 2 1 2.92 8.2 
9.  CONTROL 50 2 2 2 2 1 2 1.8 7.7 
10.  CONTROL 46 1 2 1 2 2 1 2 8.1 
11.  CONTROL 58 1 2 2 1 2 2 1.69 8 
12.  CONTROL 53 1 2 2 1 2 1 2.12 8.2 
13.  CONTROL 66 1 2 2 2 1 2 2.41 8.5 
14.  CONTROL 50 1 1 1 2 2 2 2 7.7 
15.  CONTROL 48 2 2 2 2 2 2 1.88 8.3 
16.  CONTROL 66 1 2 2 2 2 2 1.98 8.2 
17.  CONTROL 55 1 2 2 1 1 1 2.4 8 
18.  CONTROL 51 1 2 2 1 2 2 2.03 8.9 
19.  CONTROL 52 1 1 2 2 2 2 2.4 7.9 
     20. CONTROL 52 2 2 2 2 2 1 2.3 8.1 
 
 
 
 
 
 
 
 
 Sex    1-Male, 2-Female 
Abbreviations in Master Chart 
D.E.CREASE Diagonal Earlobe Crease    LWMI  Lateral Wall Myocardial 
Infarction 
FAMILY HIST. Family History of coronary artery disease IWMI   Inferior Wall Myocardial 
Infarction  
SMOKING         PWMI  Posterior Wall Myocardial 
Infarction  
SYS.H.T  Systemic Hypertension    RVMI   Right Ventricular Myocardial 
Infarction  
DIA.MELL.  Diabetes Mellitus     EJEC.FRA  Ejection Fraction  
PRE.M.I  Previous Myocardial Infarction   CLOT    
ON.ASP.  On Aspirin       REC OF ANGINA Recurrence of Angina 
PLAT.COUNT Platelet Count      SUR.WITH.COMP Survived with Complication 
MPV   Mean Platelet Volume    ARRHYTHMIA  
AWMI  Anterior Wall Myocardial Infarction  DEATH  
 
 
For these Parameters 1-Yes, 2-No. 
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 APPENDIX III 
ABBREVIATIONS AND ACRONYMS 
ADP  - Adenosine diphosphate  
AWMI - Anterior Wall Myocardial Infarction  
BP  - Blood Pressure 
CAD  - Coronary Artery Disease 
IWMI  - Inferior Wall Myocardial Infarction 
LWMI - Lateral Wall Myocardial Infarction 
MI  - Myocardial Infarction 
MPV  - Mean Platelet Volume 
NO  - Nitric Oxide  
PGI2  - Prostacyclin 
PWMI - Posterior Wall Myocardial Infarction 
RVMI  - Right Ventricular Myocardial Infarction 
vWF  -Von Willebrand factor. 
 
